Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Prostate Cancer

Free Subscription 22.06.2020 2 BMC Cancer 1 Br J Cancer 5 Eur Urol 2 Int J Radiat Oncol Biol Phys 4 Lancet Oncol 1 PLoS One 1 Proc Natl Acad Sci U S A 4 Prostate 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Cancer

1. LI Q, Shi Y, Sa R, Hao J, et al
   Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.
   BMC Cancer. 2020;20:555.
   PubMed         Abstract available
   
   
2. LIN E, Garmo H, Van Hemelrijck M, Adolfsson J, et al
   Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study.
   BMC Cancer. 2020;20:551.
   PubMed         Abstract available
   
   

   
   Br J Cancer

3. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
   Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
   Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
   PubMed         Abstract available
   
   

   
   Eur Urol

4. LEBASTCHI AH, George AK, Polascik TJ, Coleman J, et al
   Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus.
   Eur Urol. 2020 Jun 9. pii: S0302-2838(20)30358.
   PubMed         Abstract available
   
   
5. NYBERG T, Frost D, Barrowdale D, Evans DG, et al
   Prostate Cancer Risk by BRCA2 Genomic Regions.
   Eur Urol. 2020 Jun 10. pii: S0302-2838(20)30345.
   PubMed         Abstract available
   
   
6. GREGUCCI F, Carbonara R, Fiorentino A
   Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
   Eur Urol. 2020 Jun 10. pii: S0302-2838(20)30412.
   PubMed        
   
   
7. MORIS L, Mottet N, Wiegel T
   Reply to Fabiana Gregucci, Roberta Carbonara, and Alba Fiorentino's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostat
   Eur Urol. 2020 Jun 11. pii: S0302-2838(20)30414.
   PubMed        
   
   
8. PADHANI AR, Villeirs G, Ahmed HU, Panebianco V, et al
   Platinum Opinion Counterview: The Evidence Base for the Benefit of Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis is Sound.
   Eur Urol. 2020 Jun 12. pii: S0302-2838(20)30416.
   PubMed        
   
   

   
   Int J Radiat Oncol Biol Phys

9. JACCARD M, Zilli T, Dubouloz A, Escude L, et al
   Urethra-sparing stereotactic body radiotherapy for prostate cancer: quality assuranceof a randomized phase II trial.
   Int J Radiat Oncol Biol Phys. 2020 Jun 11. pii: S0360-3016(20)31242.
   PubMed         Abstract available
   
   
10. PARIKH NR, Chang EM, Nickols NG, Rettig MB, et al
    Cost-effectiveness of metastasis-directed therapy in oligorecurrent hormone-sensitive prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jun 13. pii: S0360-3016(20)31250.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

11. GOURD E
    New advances in prostate cancer screening and monitoring.
    Lancet Oncol. 2020 Jun 11. pii: S1470-2045(20)30349.
    PubMed        
    
    
12. GHADJAR P, Wiegel T
    Androgen deprivation therapy plus salvage radiotherapy after prostatectomy.
    Lancet Oncol. 2020;21:e11.
    PubMed        
    
    
13. CARRIE C, Chabaud S
    Androgen deprivation therapy plus salvage radiotherapy after prostatectomy - Authors' reply.
    Lancet Oncol. 2020;21:e13.
    PubMed        
    
    
14. BIRER S, Spratt DE
    Androgen deprivation therapy plus salvage radiotherapy after prostatectomy.
    Lancet Oncol. 2020;21:e12.
    PubMed        
    
    

    
    PLoS One

15. SHIN D, Shim SR, Kim CH
    Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy.
    PLoS One. 2020;15:e0234264.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

16. BICAK M, Luckerath K, Kalidindi T, Phelps ME, et al
    Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted alpha-particle therapy.
    Proc Natl Acad Sci U S A. 2020 Jun 12. pii: 1918744117.
    PubMed         Abstract available
    
    

    
    Prostate

17. LEU WJ, Wang CT, Hsu JL, Chen IS, et al
    Ascleposide, a natural cardenolide, induces anticancer signaling in human castration-resistant prostatic cancer through Na(+) /K(+) -ATPase internalization and tubulin acetylation.
    Prostate. 2020;80:305-318.
    PubMed         Abstract available
    
    
18. WANG K, Chen Z, Shi J, Feng Y, et al
    Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells.
    Prostate. 2020 Jun 15. doi: 10.1002/pros.24029.
    PubMed         Abstract available
    
    
19. BEGEMANN D, Wang Y, Yang W, Kyprianou N, et al
    Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Prostate. 2020 Jun 16. doi: 10.1002/pros.24015.
    PubMed         Abstract available
    
    
20. WU Z, Wang K, Yang Z, Pascal LE, et al
    A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR(F876L) nuclear import and function.
    Prostate. 2020;80:319-328.
    PubMed         Abstract available
    
    

    
    Urology

21. WAKE N, Nussbaum JE, Elias MI, Nikas CV, et al
    3D Printing, Augmented Reality, and Virtual Reality for the Assessment and Management of Kidney and Prostate Cancer: A Systematic Review.
    Urology. 2020 Jun 11. pii: S0090-4295(20)30663.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: